Interv Akut Kardiol. 2009;8(5):269-270

AURORA study. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

Jiří Vítovec1, Jindřich ©pinar2
1 I. interní kardioangiologická klinika FN u sv. Anny v Brně
2 Interní kardiologická klinika FN a LF MU v Brně

The AURORA study included 2,776 patients who had been in a regular dialysis programme for at least 3 months. Following randomization,

the patients received rosuvastatin at a dose of 10 mg/day or placebo. The combined primary endpoint was cardiovascular death,

nonfatal myocardial infarction, or stroke. The study failed to demonstrate an effect of treatment with rosuvastatin on reducing cardiovascular

events in dialysis patients.

Keywords: statins, endstage renal disease, hemodialysis, cardiovascular events.

Published: November 20, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. AURORA study. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. Interv Akut Kardiol. 2009;8(5):269-270.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41: 11-17. Go to original source... Go to PubMed...
    2. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients. JAMA 2004; 291: 451-459. Go to original source... Go to PubMed...
    3. AURORA Study Group: Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med 2009; 360: 1395-1407. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.